A Phase 3, Randomized, Double-Blind Study Of Pembrolizumab Versus Placebo In Combination With Paclitaxel With Or Without Bevacizumab For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-Ov65)